Status:
COMPLETED
REcanalization of Distal Cerebral Vessels in Acute Stroke Using ApeRio®
Lead Sponsor:
Acandis GmbH
Conditions:
Acute Stroke
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of the REVISAR PMCF is to collect data in clinical practice of the APERIO® and APERIO® Hybrid(17) Thrombectomy Device, which are intended to restore blood flow in the neurovasculature by r...
Detailed Description
Study Type: prospective, multicenter, single-arm, open-label, national Participants: 11 participating centers in Germany PI: Dr. Franziska Dorn, University Hospital Bonn, Germany Estimated Enrolmen...
Eligibility Criteria
Inclusion
- Any patient treated with the APERIO® or APERIO® Hybrid(17) Thrombectomy Device due to occlusion in distal vessel of the anterior and posterior circulation (postbifurcal MCA, ACA, PCA) according to IFU
- Age ≥ 18 years
Exclusion
- pre stroke mRS ≥ 3
- Any contraindication according to IFU
Key Trial Info
Start Date :
July 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2024
Estimated Enrollment :
134 Patients enrolled
Trial Details
Trial ID
NCT04479020
Start Date
July 1 2020
End Date
May 1 2024
Last Update
December 6 2024
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Schlosspark Klinik Charlottenburg
Berlin, Germany
2
Universitätsklinikum Bonn
Bonn, Germany, 53127
3
Universitätsklinikum Köln
Cologne, Germany
4
Universitätsklinikum Düsseldorf
Düsseldorf, Germany